Clinical Events After Discontinuation of {beta}-Blockers in Patients Without Heart Failure Optimally Treated After Acute Myocardial Infarction: A Cohort Study on the French Healthcare Databases [Original Articles]

Conclusions:
In routine care of patients without heart failure, revascularized and optimally treated after AMI, discontinuation of β-blockers beyond 1 year after AMI was associated with an increased risk of death or readmission for ACS, while statistical significance was not reached for the association with all-cause mortality. A contemporary randomized clinical trial is needed to precise the role of β-blockers in the long-term treatment after AMI.

Source: Circulation: Cardiovascular Quality and Outcomes - April 13, 2018 Category: Cardiology Authors: Neumann, A., Maura, G., Weill, A., Alla, F., Danchin, N. Tags: Cardiovascular Disease, Epidemiology, Secondary Prevention, Chronic Ischemic Heart Disease, Mortality/Survival Original Articles Source Type: research